The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Tolerability and Clinical Activity of Post-Transplantation Azacitidine in Patients Allografted for Acute Myeloid Leukemia Treated on the RICAZA Trial
Open accessAbstract
Disease relapse is the major causes of treatment failure after allogeneic stem cell transplantation (SCT) in patients with acute myeloid leukemia (AML). As well as demonstrating significant clinical activity in AML, azacitidine (AZA) upregulates putative tumor antigens, inducing a CD8(+) T cell response with the potential to augment a graft-versus-leukemia effect. We, therefore, studied the feasibility and clinical sequelae of the administration of AZA during the first year after transplantation in 51 patients with AML undergoing allogeneic SCT. Fourteen patients did not commence AZA either because of transplantation complications or withdrawal of consent. Thirty-seven patients commenced AZA at a median of 54 days (range, 40 to 194 days) after transplantation, which was well tolerated in the majority of patients. Thirty-one patients completed 3 or more cycles of AZA. Sixteen patients relapsed at a median time of 8 months after transplantation. No patient developed extensive chronic graft-versus-host disease. The induction of a post-transplantation CD8(+) T cell response to 1 or more tumor-specific peptides was studied in 28 patients. Induction of a CD8(+) T cell response was associated with a reduced risk of disease relapse (hazard ratio [HR], .30; 95% confidence interval [CI], .10 to .85; P = .02) and improved relapse-free survival (HR, .29; 95% CI, .10 to .83; P = .02) taking into account death as a competing risk. In conclusion, AZA is well tolerated after transplantation and appears to have the capacity to reduce the relapse risk in patients who demonstrate a CD8(+) T cell response to tumor antigens. These observations require confirmation in a prospective clinical trial.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fenaux, P., Mufti, G. J., Hellstrom-Lindberg, E., Santini, V., Finelli, C., Giagounidis, A., Schoch, R., Gattermann, N., Sanz, G., List, A., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70003-8 · Cited by 2,663 · cited 1×
“Azacitidine (AZA) is a DNA methyltransferase inhibitor that demonstrates significant clinical activity in AML and myelodysplasia [12,13] and can also be an effective salvage therapy in patients who relapse after allogeneic transplantation [14,15].”
Background
Cited by
Döhner, H., Estey, E., Grimwade, D., Amadori, S., Appelbaum, F. R., Büchner, T., Dombret, H., Ebert, B. L., Fenaux, P., Larson, R. A., et al. (2017) · Blood · doi:10.1182/blood-2016-08-733196 · Cited by 5,775
de Witte, T., Bowen, D., Robin, M., Malcovati, L., Niederwieser, D., Yakoub-Agha, I., Mufti, G. J., Fenaux, P., Sanz, G., Martino, R., et al. (2017) · Blood · doi:10.1182/blood-2016-06-724500 · Cited by 379
Platzbecker, U., Middeke, J. M., Sockel, K., Herbst, R., Wolf, D., Baldus, C. D., Oelschlägel, U., Mütherig, A., Fransecky, L., Noppeney, R., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30580-1 · Cited by 345
Immune escape and immunotherapy of acute myeloid leukemia
Vago, L., & Gojo, I. (2020) · Journal of Clinical Investigation · doi:10.1172/jci129204 · Cited by 341
Current status and new treatment approaches in TP53 mutated AML
Hunter, A. M., & Sallman, D. A. (2019) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2019.05.004 · Cited by 102
Craddock, C., Slade, D., De Santo, C., Wheat, R., Ferguson, P., Hodgkinson, A., Brock, K., Cavenagh, J., Ingram, W., Dennis, M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00889 · Cited by 73
Self-citation
Metadata
- Authors
- Craddock, C., Jilani, N., Siddique, S., Yap, C., Khan, J., Nagra, S., Ward, J., Ferguson, P., Hazlewood, P., Buka, R., Vyas, P., Goodyear, O., Tholouli, E., Crawley, C., Russell, N., Byrne, J., Malladi, R., Snowden, J., & Dennis, M.
- Venue
- Biology of Blood and Marrow Transplantation
- Publisher
- Elsevier BV
- Published
- 2016-02
- Volume
- 22
- Issue
- 2
- Pages
- 385-390
- ISSN
- 1083-8791 (ISSN-L)
- OpenAlex
- W1415829101
- Cited by
- 175
- References
- 1
- FWCI
- 12.89
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.